List view / Grid view
30 July 2014 | By kdm communications
Avacta Analytical has released a number of software updates for its innovative Optim® series of biophysical characterization instruments...
29 July 2014 | By Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy®...
29 July 2014 | By GlobalData
The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value...
29 July 2014 | By Janssen
... in all oral 12-week combination with sofosbuvir for genotype 1 chronic hepatitis C.
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
29 July 2014 | By Johnson & Johnson
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1 The FDA also approved IMBRUVICA for CLL patients with del 17p,1 a genetic…
29 July 2014 | By Novartis
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada...
Clinical laboratories around the world are helping to improve patient care while navigating an evolving healthcare environment. To help laboratories with increasing demands, Abbott (NYSE: ABT) is developing diagnostic solutions for today and tomorrow, which it will showcase during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical…
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
28 July 2014 | By FT Live
The future is arriving fast for the life science industry...
25 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray)...
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval.
24 July 2014 | By Roche
Pharmaceutical giant Roche delivers its first-half results for 2014...
24 July 2014 | By Novartis
Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim...
